About Us

Elastin is a critical component of tissues in the human body which require the ability to stretch and recoil, such as the skin, lungs, arteries, elastic ligaments.  Elastagen has developed a synthetic version of the elastin protein which is identical to that naturally present in the human body.

Elastagen’s platform technology has potential applications in a number of areas including skin rejuvenation, scar remodelling and tissue repair.

Elastagen was founded following the acquisition of intellectual property rights to the elastin technology which was developed by Prof Weiss at the University of Sydney. The Company has since successfully attracted capital from a number of leading Australian and overseas life science venture capital groups.

Elastagen’s operations have expanded from its Australian base to include production in Europe and clinical operations in the UK.

Our People | Team

Rob Daniels


Rob Daniels


Rob has successfully guided Elastagen from its early research phases through to the current clinical development of its tropoelastin based treatments for the rapidly growing medical and aesthetic markets.

Prior to joining Elastagen Rob had spent the previous ten years working across a broad range of the life science industry including contract research, medical devices and therapeutics. He has been successful in raising capital; managing in- and out- licensing programs; joint venture creation; and, managing product development programs through to the clinic. Robert’s experience includes University spin-outs through to listed companies; and, he has worked in the UK, Australia and Hong Kong.

Most recently he was VP Asia Pacific for PharmaVentures Ltd, a boutique transaction advisory firm specialising in the life sciences. Prior to that Robert was Chief Commercial Officer at Novathera Ltd where he gained significant domain experience in the regenerative medicine field.

Robert has a PhD from University College London and a Masters in Entrepreneurship and Innovation from the Australian Graduate School of Entrepreneurship.




John St Clair Roberts (MRCS LRCP FFPM)


Having graduated in medicine from the Royal College of Surgeons in Ireland, John chose to specialise in Pharmaceutical Medicine after spending several years practicing hospital-based medicine in the UK, and working for the flying-doctor service in Kenya.

Within the pharmaceutical industry, he has since gained significant development and business experience in a broad range of therapeutic areas including vaccination, immunotherapy, infectious disease, oncology, wound healing, aesthetics, regenerative medicine and addiction. John has first-hand experience of all phases of clinical development with a particular emphasis on practical design and fast track delivery of phase I and phase II proof-of-concept studies.

He has a strong commercial awareness having held senior management and executive board positions in both private and public pharmaceutical companies including Merieux UK (now Sanofi-Pasteur MSD), Cantab Pharmaceuticals plc, Xenova Group plc, Microscience plc and Intercytex plc. John has been responsible for numerous clinical studies in Europe, North America, Australasia, India and Vietnam.




Michal Graff Mitzmacher


Michal has driven the transition of Elastagen’s technology from proof of concept production runs through scale up to commercial production and industrial processes; enabling Elastagen’s unique tropoelastin based materials to be produced to the required economies of scale. In addition, Michal has been central to Elastagen’s partnering activities with responsibility for the capture, communication and transfer of Elastagen’s technology to and from partner facilities.

Michal is an accomplished Engineer with significant experience in the Pharmaceuticals, Medical Device and Biotechnology industries. Michal’s experience includes deep hands-on roles in all aspects of pharmaceutical research, production, scale up and design, as well as in the construction, commissioning, simulation and operation of industrial processes and clean systems.

Most recently she was Project Leader & Senior Engineer for Biopharmax LTD, a boutique design and construction consultancy firm specialising in the life sciences. One of her roles at Biopharmax was as project engineer for Omrix and subsequently J&J; a role which included the scale-up of production processes for the manufacture of their fibrin biomaterial; the design, construction, commission and simulation of the production plant; together with close liaison and coordination with the client.

Michal has a M.Sc in Bio-material Engineering from Tel-Aviv University and a B.Sc in Chemical Engineering from the Technion, Israel.




John Westwater


John is our Chief Financial Officer and joined the Company in 2015. He has over thirteen years experience in the life science financial industry, eight years as a venture capital investor and remainder as an investment banking professional.

Prior to joining Elastagen he was at Phase4 Ventures (formerly Nomura Phase4 Ventures), a global life science VC firm based in London. During this period he was actively involved with several investments both in the US and Europe: including Nabriva Therapeutics, Paratek Pharmaceuticals, Zosano Pharma and Acadia Pharmaceuticals.

John has also spent over four years with Morgan Stanley in their healthcare corporate finance and Mergers & Acquisitions teams. During this period he had a key role in the development and execution of Elan Corp’s recovery plan between 2002 and 2003, which involved over $1Bn in disposal proceeds and the restructuring of its balance sheet, as well as several biotech initial public offerings.
He holds a PhD and BSc (Hons) in Biochemistry from Heriot-Watt University in Scotland and was awarded the Watt Club Medal.




Emma McGilly


Emma is Elastagen’s Administrative and Executive Assistant with over 20 years experience in administration, office management and customer service.

Prior to Elastagen, Emma worked as a Firm Administrator for Webb Henderson, a premium international legal and regulatory practice; Office Manager and Administrative Assistant at Sweeney Vesty, a business strategy and communications company providing services to corporations and public organisations; and, as an Export Co-ordinator for PSM Healthcare Ltd (now API Consumer Brands), a world-class company in manufacturing healthcare, pharmaceutical and skincare products in New Zealand.




Sean Kearney


Sean is the Quality Assurance Manager at Elastagen and joined the Elastagen team in mid-2017. He has almost 10 years experience in the medical device and medical laboratory industries and has spent the last 4 years working as a Quality Assurance Manager at a medical device company.

Sean has many years of experience building, implementing and maintaining quality management systems which are compliant with medical device standards such as ISO 13485 and 21 CFR 820. Sean has guided teams through FDA, TGA and Notified Body audits successfully to date.

Most recently, Sean was the Quality Assurance Manager for Clinical Genomics, a biotechnology company based in Sydney, Australia which develops innovative products for colorectal cancer diagnosis and monitoring. Prior to working at Clinical Genomics, Sean worked in Quality Assurance at Abbott Diagnostics Division based in Longford, Ireland.

Sean has a B.Eng in Biomedical Engineering from the National University of Ireland, Galway.

Our People | Board


Rob Daniels


Rob has successfully guided Elastagen from its early research phases through to the current clinical development of its tropoelastin based treatments for the rapidly growing medical and aesthetic markets.

Prior to joining Elastagen Rob had spent the previous ten years working across a broad range of the life science industry including contract research, medical devices and therapeutics. He has been successful in raising capital; managing in- and out- licensing programs; joint venture creation; and, managing product development programs through to the clinic. Robert’s experience includes University spin-outs through to listed companies; and, he has worked in the UK, Australia and Hong Kong.

Most recently he was VP Asia Pacific for PharmaVentures Ltd, a boutique transaction advisory firm specialising in the life sciences. Prior to that Robert was Chief Commercial Officer at Novathera Ltd where he gained significant domain experience in the regenerative medicine field.

Robert has a PhD from University College London and a Masters in Entrepreneurship and Innovation from the Australian Graduate School of Entrepreneurship.



Andrew Sneddon


Andrew was appointed to the Board of Elastagen Pty Ltd as Chairman in September 2008. Andrew is a former partner of PricewaterhouseCoopers (PWC). In his PWC role, Andrew led the technology practise for a period of time and specialised in fast growth and emerging technology companies working with many companies from start-ups to successful global corporations.

In more recent years he was the partner leading the firm’s Australian Life Sciences Practice. Andrew has extensive experience in a wide range of technical areas including mergers and acquisitions, business and strategic planning, audit, valuation, capital raising and stock exchange listings on the Australian, NASDAQ and London Stock Exchanges.

He has worked across a broad range of industries and is currently a Non-Executive Director of Innate Immunotherapeutics Limited, ClearView Wealth Limited and the Chairman of ServiceRocket Inc, Fusion Payments Limited and TGR BioSciences Pty Ltd. He is also a member of the Audit and Compliance Committees of the Crescent Capital Private Equity Funds.


Xavier Yon


Xavier Yon is a seasoned healthcare executive with an extensive background in dermatology. Previous roles include executive positions with Pfizer, Solvay, Alcon and most notably as CEO of Galderma for 17 years. During his time at Galderma he built the company from its initial spin out from Alcon to be a world leader in ethical dermatology.

Galderma currently has over 3,000 employees and $2 Billion in revenue. More recently Xavier has served as a Director of Graceway Pharmaceuticals (USA), which was acquired by Medicis in 2011. In addition to his position with Elastagen, Xavier currently serves as a board member of Photocure (Norway), a pioneer of Photo Dynamic Therapy, and Virbac (France), a global leader in animal health.

Xavier holds a degree in Physics, Chemistry and Biology from Sorbonne University, Paris and attended the Advanced Management Program at Harvard University.


Brigitte Smith

B Chem Eng, MBA, MALD


Brigitte Smith has twenty years experience in venture capital, business strategy and start-up company operations. Brigitte has been investing and managing investments for GBS’s $450m of life science specialised venture capital funds since 1998. Brigitte is on the board of GBS portfolio companies AirXpanders Inc, Elastagen Pty Ltd, Endoluminal Systems Pty Ltd, Neurovance Inc, and Vivive Inc. Brigitte was the founding investor and chair of Pharmaxis Pty Ltd.

Prior to founding GBS Brigitte worked in the US and Australia in operating roles with early stage technology based companies, and at Bain & Company as a strategic management consultant. Ms Smith has a B. Chem Eng (Honours) from the University of Melbourne, and as a Fulbright Scholar completed a MBA (Honours) from the Harvard Business School and a MALD from the Fletcher School of Law and Diplomacy, both in Boston, USA. Ms Smith has also been an adjunct lecturer in Entrepreneurial Finance at Melbourne Business School.


Stephen Thompson


Stephen is a founding partner of Brandon Capital Partners. Previously Stephen worked with Bio Innovation SA and helped establish Terra Rossa Capital, a dedicated life science Fund Manager in Adelaide.

Prior to this Stephen was a Director of Apax Partners a leading international private equity group based in London. During this time he was also a Director of Imperial Innovations, the commercialisation company of Imperial College London. Before joining Apax Partners, he fulfilled roles in product development with UK biotechnology company Cantab Pharmaceuticals. Earlier, Stephen spent ten years as a research immunologist in London and California.

Stephen is a Director of Elastagen P/L, MiReven P/L, Vaxxas P/L, Helmedix P/L, Auspherix P/L and Council Member of the Australian Venture Capital Association Limited (AVCAL). Stephen has an Honours degree in Immunology and Biochemistry, a PhD in Immunology from Kings College London and an MBA, specialising in Entrepreneurship, from Imperial College London. Stephen is a Graduate of the Australian Institute of Company Directors and a member of AusBiotech.


Marc Gleeson


Marc Gleeson has spent the last 23 years working in the Biotech and Life Sciences Industry. After starting his career as a sales representative, Marc has worked across a wide range of disciplines with increasing responsibility as well as across various geographies.

Marc spent 14 years at Allergan Inc where he worked across both the Ophthalmology and Botox Cosmetic Franchises.

Marc’s most recent role at Allergan was Vice President, US Marketing for Glaucoma and External Disease and prior to that Marc spent 7 years in the Global Strategic Marketing group at Allergan based in Irvine California, first as Senior Director, Global Strategic Marketing Retina and from the beginning of 2010 to the end of 2013 as the Vice President of Global Strategic Marketing – Eye Care. Marc’s role within the Global Strategic Marketing group was to lead the global commercial strategy for the Allergan Eye Care Franchise as well as the Business Development strategies for the Eye Care Franchise. Prior to moving to the US with Allergan Marc was responsible for both the Ophthalmology and Botox Cosmetic

Most recently Marc was the Vice President of Global Marketing for a South San Francisco start up, Oculeve Inc that is developing a treatment for Dry Eye. In July 2015 Oculeve was acquired by Allergan.


Sangwoo Lee


Sangwoo has 18 years of industrial experiences in diverse area and companies in IT including Samsung Electronics, Dasan networks, and successful venture startups of Neomtel and Polidigm. His diverse area of experience covers from IT engineering skills like sw design/development, algorithm design/implementation, network protocol to service planning and company management. In startups of Neomtel and Polidigm, Sangwoo led the core engineering development as CTO. Neomtel introduced a new service concept of mobile image compression and transmission at 2000 and its graphice technology became a de-facto standard in Korea at early 2000s. The technology was adapted by Qualcomm later and the company went IPO at 2007.

Sangwoo is responsible for global expansion of Korea Investment Partners and actively exploring cross-border investments. Current investment portfolio of Sangwoo is diverse from BIO-Healthcare companies like Elastagen, Auris Surgical Robotics, KAHR to IT companies.

Sangwoo received his B.S. and M.S. in Control and Instrumentation Engineering from Seoul National University . He is a fluent English speaker.

Our People | Scientific Advisors

Tony Weiss
Prof Tony Weiss
Founder / Lead Scientific Advisor


Professor Tony Weiss is the world leader in human tropoelastin and elastin research and its applications. A multiple University prize winner, Fulbright Scholar and learned society medalist, he is the main inventor and scientific expert behind the Intellectual Property licensed by Elastagen from the University of Sydney.

He is the Professor of Biochemistry & Molecular Biotechnology at the University of Sydney and holds multiple visiting and honorary appointments nationally and internationally. He is a Fellow of the Royal Society of Chemistry, Fellow of the Australian Academy of Technological Sciences and Engineering, Fellow of the American Institute for Medical and Biological Engineering, Fellow of the Royal Society of Arts and Fellow of the Australian Institute of Company Directors. He is on the Editorial Boards of ACS Biomaterials Science and Engineering, Biomacromolecules, Biomaterials, Biomedical Materials, BioNanoScience and Tissue Engineering.

He established the leading international human tropoelastin research laboratory and for over the past two decades has significantly increased our understanding of the expression, handling and applications of human tropoelastin.

Our People | Investors

Elastagen is a venture capital backed private company and has been successful in attracting funding from some of the leading life science investment groups.


Brandon Capital Partners

Brandon Capital Partners was founded in 2007 and makes seed and venture capital investments into emerging businesses in the high-growth life science industry. In addition to capital, Brandon enables entrepreneurs to access the resources needed to build successful businesses. We approach each investment as a collaborative alliance. Brandon’s team has a track record of successful life science investment as well as a history of working in research, operations and business development in the life sciences industry.

For more information on Brandon Capital Partners please visit:


GBS Venture Partners

Founded in 1996, GBS invests in young businesses developing and commercialising products which, when combined with the right management and finance, will make a significant difference to patients’ lives and deliver financial returns for our investors. Our areas of particular interest and expertise include human healthcare, biotechnology product development and life science start-ups. In particular, recent investments have included biological or small molecule therapeutics, medical devices and diagnostics.

For more information on GBS Venture Partners please visit:

Investor KIP

Korean Investment Partners

Korea Investment Partners (KIP) is the leading private equity and venture investment firm based in Korea, with offices in Seoul, Beijing and Shanghai, and is set to establish a US office in Silicon Valley in 2016. KIP has been discovering, investing in and promoting growth of promising businesses since its establishment in 1986, and since 2000, has been managing approximately $2 billion venture capital funds.

For more information on KIP please visit:

Investor Amore Pacific Group


AMOREPACIFIC, based in Seoul, South Korea, is a leading global beauty company based in Asia, with annual revenue of approximately $5 billion. AMOREPACIFIC Ventures, the corporate venture fund of AMOREPACIFIC, focuses on innovative technologies in the beauty and aesthetic areas.

For more information on AMOREPACIFIC Ventures please visit:

Investor Wellcome Trust

Wellcome Trust

The Wellcome Trust is a global charitable foundation dedicated to improving health. We support bright minds in science, the humanities and the social sciences, as well as education, public engagement and the application of research to medicine. Our investment portfolio gives us the independence to support such transformative work as the sequencing and understanding of the human genome, research that established front-line drugs for malaria, and Wellcome Collection, our free venue for the incurably curious that explores medicine, life and art.

For more information on the Wellcome Trust please visit:

Cell Innovation Partners

Cell Innovation Partners

Cell Innovation Partners (CIP), based in Japan, is a venture capital fund focusing exclusively on global regenerative medicine and stem cell technologies. CIP was founded in 2014 by ReproCELL, a stem cell medical research company, and Shinsei Corporate Investment, a subsidiary of Shinsei Bank. CIP supports its investee companies through its expertise and broad network in business development, R&D and finance.

For more information on CIP please visit:


BizCapital Pty Ltd

BizCapital is the investment fund of ATP Innovations – Australia’s leading business incubator. ATP Innovations has a portfolio of over 50 companies in the life sciences, engineering and information technology sectors. The company is based at the Australian Technology Park, delivering value to early-stage companies and accelerating their path to success. ATP Innovations is owned by four of Australia’s premier universities – the University of Sydney, the University of New South Wales, the Australian National University and the University of Technology, Sydney.

For more information on bizCapital and ATP Innovations please visit:

In addition to the above private investment Elastagen has also received significant support from programs managed by both the NSW State government (NSW Medical Devices Fund, NSW Biobusiness, DSRD) and Australian Federal government (NCRIS, R&D tax offset and Export Market Development).

Our Technology

Elastagen is a medical company with an advanced pipeline of products based on recombinant human tropoelastin, the building block of elastin.

Elastin is a critical physical and biological component of human tissues, such as the skin, lungs, arteries, and elastic ligaments, and is comprised of multiple copies of the protein tropoelastin.

Elastin is produced in the body predominantly during foetal development and by the time we reach adulthood the ability of the body to express tropoelastin and regenerate new elastin is minimal.

The application of tropoelastin and/or elastin as a medical biomaterial has to date been limited due to the inability to extract the protein in a functional form from animal tissues or produce it synthetically.

Elastagen, through its founding scientist Prof Weiss and his team at the University of Sydney, has acquired a unique and dominant position in the tropoelastin and elastin field.  Elastagen is the first and only provider of full length, scalable, commercial cGMP clinical grade human tropoelastin. Furthermore, Elastagen has pioneered the scientific understanding of tropoelastin and the “elastagenesis” process and developed and patented a range of approaches to formulate tropoelastin for application in tissue repair.

Tropoelastin has huge advantages for a range of medical applications, including its unique physical elastic properties and its ability to support cell growth and tissue repair. In addition, as a recombinant human biomaterial our tropoelastin based polymers have an ideal biocompatibility profile and no immune rejection problems.

Elastagen’s vision is to exploit the unique properties of the elastin material in its target medical applications through to clinical proof of concept prior to partnering for market entry and sales.

Our Products

Elastagen has an advanced portfolio of products built on scientific and clinical excellence which has been validated by preclinical and clinical studies.

Elastagen Pipeline


The latest Elastagen media coverage and break throughs

Allergan to Acquire Elastagen to Access Next Generation Injectable Portfolio
February, 2018

Elastagen to Feature Breakthrough Tissue Repair and Aesthetic Platform at Upcoming Dermatology Summit and Biotech Showcase Conferences in San Francisco, CA
January, 2018

Engineering a highly elastic human protein–based sealant for surgical applications
October, 2017

‘Squirtable’ elastic surgical glue seals wounds in 60 seconds
October, 2017

Elastagen receives $4m from NSW Health Medical Devices Fund 2016
October, 2016

Cell Innovation Partners, Japanese venture group, invests in Elastagen as part of a Second Close to the Series B Equity Financing
June, 2016

Elastagen Completes A$13m Series B Equity Financing
January, 2016

New Grants to Support Research Commercialisaton
April 15, 2015

Wellcome Trust Support for Transformative Tropoelastin Biomaterials
January, 2015

ELA presents at 7th Annual Biotech Showcase 2015 – San Francisco
January 13, 2015

Elastagen featured in Ahead of the Curve – Future Proof: The Investment Case for Biotech
December, 2014

ELA presents at Australia Biotech Invest 2014 – Melbourne
December 4, 2014

Elastagen presents at The 19th MedTech Investing Europe Conference – Paris
September 23, 2014

Elastagen recipient of inaugural NSW Health Medical Devices Fund 2013
July 15, 2013

Clinical Program Demonstrates Role for Elastin Products in Skin Repair and Rejuvenation
December 20, 2012

Elastagen Strengthens Board with Appointment of Xavier Yon
December 3, 2011

Elastagen Featured in Prime Magazine
October 11, 2011

Elastagen Expands Clinical Program for Elastin Products
September 11, 2011

The Science of Elastin
February, 2011

Skin Elastin Products A Significant Step Closer
December 11, 2009

Elastagen Secures Financing and Appoints Management Team
December 11, 2008


Literature resources to help you understand our processes and technology


Tropoelastin Implants That Accelerate Wound Repair
Suzanne M. Mithieux, Behnaz Aghaei-Ghareh-Bolagh, Leping Yan, Kekini V. Kuppan, Yiwei Wang, Francia Garces-Suarez, Zhe Li, Peter K. Maitz, Elizabeth A. Carter, Christina Limantoro, Wojciech Chrzanowski, David Cookson, Alan Riboldi-Tunnicliffe, Clair Baldock, Kosuke Ohgo, Kristin K. Kumashiro, Glenn Edwards, and Anthony S. Weiss*

Adv. Healthcare Mater. 2018, 1701206


Design of an Elastin-Layered Dermal Regeneration Template
Mithieux SM, Weiss AS

Science Direct. 2017 Apr; 52:33-40


Tropoelastin Coated PLLA-PLGA Scaffolds Promote Vascular Network Formation
Landau S, Szklanny AA, Yeo GC, Shandalov Y, Kosobrodova E, Weiss AS, Levenberg S

Biomaterials. 2017 Apr; 122:72-82


Uncovering the Secrets of Elastin
Weiss AS (Interview)

Australasian Biotechnology. 2017 Apr; Vol 27 (1)


Promoting Tropoelastin Expression in Arterial and Venous Vascular Smooth Muscle Cells and Fibroblasts for Vascular Tissue Engineering
Rothuizen TC, Kemp R, Duijs JM, de Boer HC, Bijkerk R, van der Veer EP, Moroni L, van Zonneveld AJ, Weiss AS, Rabelink TJ, Rotmans JI

Tissue Engineering Part C: Methods. 2016 Oct; 22(10):923-931


Perspectives on the Molecular and Biological Implications of Tropoelastin in Human Tissue Elasticity
Weiss AS

Australian Journal of Chemistry. 2016 Sep; 69, 1380–1382


Elastic Proteins and Elastomeric Protein Alloys
Aghaei-Ghareh-Bolagh B, Mithieux SM, Weiss AS,

Current Opinion in Biotechnology. 2016 Jun; 39:56-60


Highly Elastic and Conductive Human-Based Protein Hybrid Hydrogels
Annabi N, Shin SR, Tamayol A, Miscuglio M, Bakooshli MA, Assmann A, Mostafalu P, Sun JY, Mithieux S, Cheung L, Tang XS, Weiss AS. Khademhosseini A

Advanced Materials. 2016 Jan; 28(1):40-9


Fabricated Elastin
Yeo GC, Aghaei-Ghareh-Bolagh B, Brackenreg EP, Hiob MA, Lee P, Weiss AS

Advanced Healthcare Materials. 2015 Nov; 4(16):2530-56


Elastin-based Biomaterials and Mesenchymal Stem Cells
Ozsvar J, Mithieux SM, Wang R, Weiss AS

Biomaterials Science. 2015 Jun; 3(6):800-9


Silk-Tropoelastin Protein Films for Nerve Guidance

White JD, Wang S, Weiss AS, Kaplan DL

Acta Biomaterialia. 2015 Mar; 14:1-10


Tropoelastin Incorporation into a Dermal Regeneration Template Promotes Wound Angiogenesis
Wang Y, Mithieux SM, Kong Y, Wang XQ, Chong C, Fathi A, Dehghani F, Panas E, Kemnitzer J, Daniels R, Kimble RM, Maitz PK, Li Z, Weiss AS

Advanced Healthcare Materials. 2015 Mar; 4(4):577-84


Elastin Based Cell – Laden Injectable Hydrogels with Tunable Gelation, Mechanical and Biodegradation Properties
Fathi A, Mithieux SM, Wei H, Chrzanowski W, Valtchev P, Weiss AS, Dehghani F

Biomaterials. 2014 Jul; 35(21):5425-35


Highly Elastic Micropatterned Hydrogel for Engineering Functional Cardiac Tissue
Annabi N, Tsang K, Mithieux SM, Nikkhah M, Ameri A, Khademhosseini A, Weiss AS

Advanced Healthcare Materials. 2013 Oct 18; 23(39)


Elastin Signaling in Wound Repair
Almine JF, Wise SG, Weiss AS

Birth Defects Research Part C: Embryo Today. 2012 Sep; 96(3):248-57


Tropoelastin Bridge Region Positions the Cell-Interactive C Terminus and Contributes to Elastic Fiber Assembly
Yeo GC, Baldock C, Tuukkanen A, Roessle M, Dyksterhuis LB, Wise SG, Matthews J, Mithieux SM, Weiss AS.

Proceedings of the National Academy of Sciences USA. 2012 Feb 21; 109(8):2878-83


Shape of Tropoelastin, the Highly Extensible Protein that Controls Human Tissue Elasticity
Baldock C, Oberhauser AF, Ma L, Lammie D, Siegler V, Mithieux SM, Tu Y, Chow JY, Suleman F, Malfois M, Rogers S, Guo L, Irving TC, Wess TJ, Weiss AS.

Proceedings of the National Academy of Sciences USA. 2011 Mar 15;108(11):4322-7


Substrate Elasticity Provides Mechanical Signals for the Expansion of Hemopoietic Stem and Progenitor Cells
Holst J, Watson S, Lord MS, Eamegdool SS, Bax DV, Nivison-Smith LB, Kondyurin A, Ma L, Oberhauser AF, Weiss AS, Rasko JE

Nature Biotechnology. 2010 Oct; 28(10):1123-8


Elastin-Based Materials
Almine JF, Bax DV, Mithieux SM, Nivison-Smith L, Rnjak J, Waterhouse A, Wise SG, Weiss AS.

Chemical Society Reviews. 2010 Sep;39(9):3371-9


Primary Human Dermal Fibroblast Interactions with Open Weave Three-Dimensional Scaffolds Prepared from Synthetic Human Elastin
Rnjak J, Li Z, Maitz PK, Wise SG, Weiss AS

Biomaterials. 2009 Nov, 30(32):6469-77


Total Synthesis and Expression in Escherichia Coli of a Gene Encoding Human Tropoelastin
Martin SL, Vrhovski B, Weiss AS

Gene. 1995 Mar 10, 154(2):159-66

Elastagen Products

R&D Product Sales

Recombinant Human Tropoelastin

Cat No: ELA-1

Description:       Tropoelastin is a 60kDa extracellular matrix protein and is the soluble precursor to elastin.

Elastin is a key mammalian extracellular matrix protein that is critical to the elasticity, compliance, and resilience of a range of tissues including the vasculature, skin, and lung. In addition to providing mechanical integrity to tissues, elastin also has critical functions in the regulation of cell behaviour.

For Research Use Only

Size:                      5mg

Price:                    $1250.00 ex GST*

(*GST Australia Only)

Freight:                POA

Placing Your Order


Orders Forms can be faxed to +61 (2) 9310 7232 or email to sales@elastagen.com.

Contact Us

For more information or product sales please contact us


Elastagen Pty Ltd,
Australian Technology Park,
National Innovation Centre,
4 Cornwallis Street,
NSW 2015,


+61 (0)2 9209 4054





Your Name (required)

Your Email (required)


Your Message

Expressions of Interest

Elastagen welcomes expressions of interest in its activities from both clinicians and commercial partners. In addition, given the preclinical and clinical platform which Elastagen has developed to date, we welcome contact from potential partners interested in the unique physical and biological properties of tropoelastin.

Elastagen ATPi